SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:4fd697e1-3796-494a-8172-9dbef9de3b03"
 

Search: onr:"swepub:oai:lup.lub.lu.se:4fd697e1-3796-494a-8172-9dbef9de3b03" > Cidofovir for BK Vi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Cidofovir for BK Virus-Associated Hemorrhagic Cystitis: A Retrospective Study

Cesaro, Simone (author)
Hirsch, Hans H. (author)
Faraci, Maura (author)
show more...
Owoc-Lempach, Joanna (author)
Beltrame, Angela (author)
Tendas, Andrea (author)
Baltadakis, Ioannis (author)
Dalle, Jean-Hughes (author)
Koc, Yener (author)
Toporski, Jacek (author)
Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine
Styczynski, Jan (author)
Yesilipek, M. Akif (author)
Heinz, Werner (author)
Caniglia, Maurizio (author)
Rascon, Jelena (author)
Fauser, Axel A. (author)
Michallet, Mauricette (author)
Lopez-Corral, Lucia (author)
Neuburger, Stefan (author)
Tridello, Gloria (author)
Einsele, Herman (author)
show less...
 (creator_code:org_t)
Oxford University Press (OUP), 2009
2009
English.
In: Clinical Infectious Diseases. - : Oxford University Press (OUP). - 1537-6591 .- 1058-4838. ; 49:2, s. 233-240
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background. BK virus-associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic hematopoietic stem cell transplantation (HSCT), but antiviral treatment for this condition has not been evaluated. Methods. We conducted a retrospective survey on the safety and outcome of cidofovir treatment for patients with BKV-HC in centers affiliated with the European Group for Blood and Marrow Transplantation. Results. From 1 April 2004 to 31 December 2007, 62 patients received a diagnosis of BKV-HC after a median interval of 35 days after HSCT (range, 3-577 days). Fifty-seven patients (92%) received intravenous cidofovir, whereas 5 patients received cidofovir intravesically. Complete response (CR) was recorded in 38 (67%) of 57 patients with HC treated with intravenous cidofovir, whereas partial response (PR) was documented in 7 patients (12%). CR was documented in 3 patients and PR in 1 patient with HC treated with intravesical cidofovir. A reduction of 1-3 logs in BKV load was documented in 8 of the 10 patients achieving CR. Mild-to-moderate toxic effects were recorded in 18 of 57 patients who received intravenous cidofovir administration. In a multivariate analysis, the factors significantly associated with response to cidofovir were the stem cell source (Pp. 01) and the use of total body irradiation (P = .03). After a median follow-up of 287 days, overall survival and total treatment-related mortality rates were 63% and 40% for patients achieving CR, compared with 14% and 72% for patients with PR or no response to cidofovir, respectively (P < .001 and P = .001, respectively). Conclusions. Cidofovir may be a potentially effective therapy for BKV-HC, but evidence supporting its use requires randomized controlled trials.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view